ASH News Daily 2014 - Day 3 - (Page A-1)
Read this issue online at
www.hematology.org/ashnewsdaily2014_monday
Follow us on Twitter using #ASH14
Schedule
9:00 - 10:00 a.m.
E. Donnall Thomas Lecture
Moscone North, Hall D
10:30 a.m. - 12:00 noon
Spotlight Sessions:
Controversy: What is the Best
Preclinical Model for Testing
Novel Therapeutics?
Venous Thromboembolism in
Vulnerable Populations
Moscone South, Esplanade 301-302
12:15 - 1:15 p.m.
Featured Topic Discussion:
Checkpoint Blockades
Moscone North, Rooms 120-125
12:15 - 1:15 p.m.
Meet the Blood Editors
Marriott Marquis, Pacific I
1:30 - 2:30 p.m.
Ernest Beutler Lecture
Moscone North, Hall D
2:45 - 4:15 p.m.
Spotlight Sessions:
Novel Agents for T-Cell Lymphoma
Weed or Soil: The Malignant Bone
Marrow Niche
Moscone South, Esplanade 301-302
4:30 - 6:00 p.m.
Special Education Session:
Newly Approved Drugs
Moscone North, Hall D
This CAR-T Has Wheels!
By laura MichaeliS, Md
I
n the world of hematologic malignancies,
seismic shifts in treatment
strategies are uncommon.
While rare, these shifts do happen
- stem cell transplantation, imatinib,
and ATRA come to mind as some of
the disruptive technologies that have
allowed patient care to accelerate
along a totally new trajectory. The accumulating
data supporting chimeric
antigen receptor T-cell (CAR-T)
therapy for diseases such as chronic
lymphocytic leukemia (CLL) and
acute lymphocytic leukemia (ALL)
highlight what may well become the
next sea change in the care of patients
with all types of hematologic neoplasia.
Yesterday's standing-room-only
scientific symposium on CAR-T cell
therapy bespoke some of the mounting
enthusiasm regarding this new
treatment strategy.
The symposium featured Dr.
Carl June, the lead translational
investigator for the University of
Pennsylvania's study of engineered
T-lymphocytes in the treatment of
patients with relapsed CLL, ALL,
and non-Hodgkin lymphoma. Those
studies and others being done at the
Dr. Steven Rosenberg presents during the Special Scientific Symposium on
Chimeric Antigen Receptor T-Cell Therapy Sunday.
National Institutes of Health (NIH),
Children's Hospital of Pennsylvania,
and Memorial Sloan Kettering paved
the way for several larger studies,
most notably those performed in
relapsed/refractory ALL. Dr. June's
discussion not only recapped some
of what has been accomplished in the
care of patients with lymphoid neoplasms,
but also outlined other possible
suitable antigen target cells, with
the hope that this type of approach
will be scalable with minimal toxicity.
"We're hoping for a fleet of CARs,"
Dr. June quipped in response to a
question from the audience about
the next likely antigens that may
be investigated. He also pointed to
the fact that the chimeric cells can
recognize even small amounts of
»» CAR-T Page A-18
Globulins du
Chyle: What
Have We Learned
About Platelets
Since 1842?
IN THIS SECTION
Sunday's Plenaries
A-2
Congenital Cures
A-4
Von Willebrand Disease
A-4
ASH/EHA Joint
Symposium
A-5
By reBecca KruSe-JarreS, Md, MPh
n a publication from 1842,
Alfred Donne, a French physician,
experimenter, microscopist,
and photographer observed, "Il existe
dans le sang trois espèces de particules."
Besides the "globules rouge"
and "globules blancs" he described
the "globulins du chyle" - small globules
derived from plasma. James
Wright (using the stain named after
him) further examined and characterized
these plasma globules and
coined them platelets in 1910. The
»» PLATELETS Page A-19
I
http://www.hematology.org/ashnewsdaily2014_monday
Table of Contents for the Digital Edition of ASH News Daily 2014 - Day 3
Table of Contents
ASH News Daily 2014 - Day 3
https://www.nxtbookmedia.com